Bruker Corp Files 8-K on Financials

TL;DR

Bruker Corp filed an 8-K on Jan 13, 2025, updating on financials.

AI Summary

On January 13, 2025, Bruker Corporation filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as a Regulation FD disclosure. No specific financial figures or new operational details were provided in the excerpt.

Why It Matters

This filing indicates Bruker Corporation is providing updates on its financial performance and operational status to the SEC, which is important for investors to monitor.

Risk Assessment

Risk Level: low — The filing is a standard 8-K reporting routine financial and operational updates without any immediate negative or positive indicators.

Key Players & Entities

• Bruker Corporation (company) — Registrant
• January 13, 2025 (date) — Date of earliest event reported
• 000-30833 (company) — SEC File Number
• 04-3110160 (company) — I.R.S. Employer Identification No.
• 40 Manning Road Billerica, MA 01821 (location) — Principal executive offices address

FAQ

Key Financial Figures

• $0.01 — nge on Which Registered Common Stock, $0.01 par value per share BRKR The Nasdaq
• $970 million — r the fourth quarter of 2024 is between $970 million and $980 million and that fourth quarte
• $980 million — ter of 2024 is between $970 million and $980 million and that fourth quarter 2024 BSI bookin

Filing Documents

• brkr-20250113.htm (8-K) — 46KB
• 0000950170-25-004646.txt ( ) — 162KB
• brkr-20250113.xsd (EX-101.SCH) — 29KB
• brkr-20250113_htm.xml (XML) — 4KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On January 13, 2025, during its scheduled presentation at the 43rd Annual J.P. Morgan Healthcare Conference, Bruker Corporation (the "Company") stated that its current preliminary expectation for revenue for the fourth quarter of 2024 is between $970 million and $980 million and that fourth quarter 2024 BSI bookings were solid. The Company also provided preliminary outlook for 2025 for constant exchange rate revenue growth of upper mid-single digits revenue assuming low-single digits market growth. A copy of the Company's presentation is available in the "Investors" section of its website at ir.bruker.com. Because the Company's financial statements for the fourth quarter and fiscal year ended December 31, 2024 have not yet been finalized or audited, this preliminary statement regarding the Company's current expectations with respect to its fourth quarter 2024 and full year 2024 revenue are subject to change, and the Company's actual revenues for these periods may differ materially from these preliminary estimates. Accordingly, you should not place undue reliance on these preliminary estimates. Section 7 – Regulation FD Disclosure

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. The information set forth in Item 2.02 of this Current Report is incorporated into this Item 7.01 by reference. The information furnished in Item 2.02 and Item 7.01 of this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. Cautionary Note Regarding Forward-Looking Statements Any statements contained in this Current Report on Form 8-K that do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our preliminary fourth quarter and fiscal year ended December 31, 2024 operational and financial performance, including our revenue growth, non-GAAP operating margin, non-GAAP EPS and non-GAAP tax rate; ROIC; EBITDA; management's expectations for future financial and operational performance, expected growth, and business outlook, including the expected financial contributions of our BNANO, CALID and BioSpin Groups in 2025-2027; statements regarding our business focus, expected market growth and market size; and product performance. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to, risks and uncertainties relating to continued volatility in the capital markets, the impact of Project Accelerate, the performance of breakout opportunities, the integration and assumption of liabilities of businesses we have acquired or may acquire in the future, fluctuations in foreign currency exchange rates

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRUKER CORPORATION (Registrant) Date: January 13, 2025 By: /s/ GERALD N. HERMAN Gerald N. Herman Executive Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR